Antifibrinolytic agents in current anaesthetic practice
Top Cited Papers
- 31 October 2013
- journal article
- review article
- Published by Elsevier BV in British Journal of Anaesthesia
- Vol. 111 (4), 549-563
- https://doi.org/10.1093/bja/aet154
Abstract
Antifibrinolytic drugs have become almost ubiquitous in their use during major surgery when bleeding is expected or commonplace. Inhibition of the fibrinolytic pathway after tissue injury has been consistently shown to reduce postoperative or traumatic bleeding. There is also some evidence for a reduction of perioperative blood transfusion. However, evidence of complications associated with exaggerated thrombosis also exists, although this appears to be influenced by the choice of the individual agent and the dose administered. There is controversy over the use of the serine protease inhibitor aprotinin, whose license was recently withdrawn but may shortly become available on the market again. In the UK, tranexamic acid, a tissue plasminogen and plasmin inhibitor, is most commonly used, with evidence for benefit in cardiac, orthopaedic, urological, gynaecological, and obstetric surgery. In the USA, ɛ-aminocaproic acid, which also inhibits plasmin, is commonly used. We have reviewed the current literature for this increasingly popular class of drugs to support clinical judgement in daily anaesthetic practice.Keywords
This publication has 98 references indexed in Scilit:
- Tranexamic acid concentrations associated with human seizures inhibit glycine receptorsJCI Insight, 2012
- Comparative analysis of antifibrinolytic medications in pediatric heart surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2012
- Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)BMJ, 2011
- The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trialThe Lancet, 2011
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trialTrials, 2010
- A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgeryBMC Surgery, 2010
- Anti-fibrinolytic agents in post partum haemorrhage: a systematic reviewBMC Pregnancy and Childbirth, 2009
- Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery BypassThe Annals of Thoracic Surgery, 2008
- Differential Effects of Epsilon-aminocaproic Acid and Aprotinin on Matrix Metalloproteinase Release in Patients Following Cardiopulmonary BypassJournal of Cardiovascular Pharmacology, 2008